NO20065696L - Piperazinderivater av alkyloksindoler som 5-HT7 reseptoraktive midler. - Google Patents

Piperazinderivater av alkyloksindoler som 5-HT7 reseptoraktive midler.

Info

Publication number
NO20065696L
NO20065696L NO20065696A NO20065696A NO20065696L NO 20065696 L NO20065696 L NO 20065696L NO 20065696 A NO20065696 A NO 20065696A NO 20065696 A NO20065696 A NO 20065696A NO 20065696 L NO20065696 L NO 20065696L
Authority
NO
Norway
Prior art keywords
alkyloxindoles
active agents
piperazine derivatives
receptor active
derivatives
Prior art date
Application number
NO20065696A
Other languages
English (en)
Inventor
Jozsef Barkoczy
Tibor Mezei
Gyula Simig
Balazs Volk
Dezsofi Rita Kapillerne
Original Assignee
Egis Gyogyszergyar Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0400956A external-priority patent/HU0400956D0/hu
Priority claimed from HU0500462A external-priority patent/HUP0500462A3/hu
Application filed by Egis Gyogyszergyar Nyrt filed Critical Egis Gyogyszergyar Nyrt
Publication of NO20065696L publication Critical patent/NO20065696L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Det beskrives nye 3,3-disubstituerte indol-2-on-derivater med den generelle formel (I). Forbindelsene er nyttige for profilakse eller terapi av forstyrrelser i sentralnervesystemet.
NO20065696A 2004-05-11 2006-12-11 Piperazinderivater av alkyloksindoler som 5-HT7 reseptoraktive midler. NO20065696L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0400956A HU0400956D0 (en) 2004-05-11 2004-05-11 Pyridine derivatives of alkyl oxindoles
HU0500462A HUP0500462A3 (en) 2005-05-05 2005-05-05 Pyridine derivatives of alkyloxindoles as 5ht7 receptor active agents
PCT/HU2005/000047 WO2005108388A1 (en) 2004-05-11 2005-05-10 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents

Publications (1)

Publication Number Publication Date
NO20065696L true NO20065696L (no) 2007-02-08

Family

ID=89985996

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065696A NO20065696L (no) 2004-05-11 2006-12-11 Piperazinderivater av alkyloksindoler som 5-HT7 reseptoraktive midler.

Country Status (18)

Country Link
US (2) US20070265300A1 (no)
EP (1) EP1751134A1 (no)
JP (1) JP2007537225A (no)
KR (1) KR20070011552A (no)
AU (1) AU2005240841A1 (no)
BG (1) BG109767A (no)
CA (1) CA2565061A1 (no)
CZ (1) CZ2006769A3 (no)
EA (1) EA010154B1 (no)
HR (1) HRP20060402A2 (no)
IL (1) IL178891A0 (no)
MX (1) MXPA06012991A (no)
NO (1) NO20065696L (no)
NZ (1) NZ551543A (no)
PL (1) PL381612A1 (no)
RS (1) RS20060619A (no)
SK (1) SK51052006A3 (no)
WO (1) WO2005108388A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
WO2017076931A1 (en) * 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
PH12018500978B1 (en) * 2015-11-06 2023-05-05 Hoffmann La Roche Indolin-2-one derivatives
EP3371170B1 (en) * 2015-11-06 2019-07-31 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives useful in the treatment of cns diseases
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
EP0937715B1 (en) * 1996-06-28 2005-06-01 Meiji Seika Kaisha Ltd. Tetrahydrobenzindole compounds
WO1998008816A1 (en) * 1996-08-26 1998-03-05 Meiji Seika Kaisha, Ltd. Oxindole derivatives and psychotropic drugs
ZA9711376B (en) * 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
DE69829317T2 (de) * 1997-12-25 2006-04-06 Meiji Seika Kaisha Ltd. Tetrahydrobenzindol-derivate
JPH11189585A (ja) * 1997-12-25 1999-07-13 Meiji Seika Kaisha Ltd ５−ｈｔ７受容体結合能を有するテトラヒドロベンズインドール誘導体
US6407112B1 (en) * 1998-04-22 2002-06-18 Meiji Seika Kaisha, Ltd. Optically active tetrahydrobenzindole derivative
JP2004231514A (ja) * 2000-08-31 2004-08-19 Meiji Seika Kaisha Ltd ５−ｈｔ７受容体結合能を有し、かつ代謝的に安定なテトラヒドロベンズインドール誘導体
AR035521A1 (es) * 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
WO2004020437A1 (en) * 2002-08-29 2004-03-11 H. Lundbeck A/S S-(+)-3-{1-[2-(2,3-dihydro-1h-indol-3-yl)ethyl]-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof
AU2005240844A1 (en) * 2004-05-11 2005-11-17 Egis Gyogyszergyar Nyrt. Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders

Also Published As

Publication number Publication date
HRP20060402A2 (hr) 2007-06-30
MXPA06012991A (es) 2007-05-04
CZ2006769A3 (cs) 2007-03-14
JP2007537225A (ja) 2007-12-20
EA200602081A1 (ru) 2007-04-27
US20090306144A1 (en) 2009-12-10
AU2005240841A1 (en) 2005-11-17
EP1751134A1 (en) 2007-02-14
KR20070011552A (ko) 2007-01-24
EA010154B1 (ru) 2008-06-30
WO2005108388A1 (en) 2005-11-17
SK51052006A3 (sk) 2007-05-03
NZ551543A (en) 2009-12-24
IL178891A0 (en) 2007-03-08
PL381612A1 (pl) 2007-06-11
BG109767A (bg) 2008-05-30
US20070265300A1 (en) 2007-11-15
CA2565061A1 (en) 2005-11-17
RS20060619A (sr) 2008-06-05

Similar Documents

Publication Publication Date Title
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
NO20062139L (no) Dihydrobenzofuranyl-alkanaminderivater som 5HT2C-agonister
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
NO20161634A1 (no) 3-Z-[1-(4-(N-((4-metyl-piperazin-1-yl)-metylkarbonyl)-N-metyl-amino)-anilino)-1-fenyl-metylen]-6-metoksykarbonyl-2-indolinon, tautomerene, diastereomerene, enantiomerene, blandinger derav og saltene derav, og i kombinasjon med en ytterligere farmakologisk aktiv substans, for anvendelse i forebygging eller behandling av fibrose ved revmatoid artritt
NO20055219L (no) Nye forbindelser
NO20044764L (no) 1-(aminoalkyl)-3-sulfonylindol og -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20066055L (no) Pyridinderivater
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
NO20050014L (no) 1-Heterosyklylalkyl-3-sulfonylindol eller -indazolderivater som 5-hydroksytryptamin-6 ligander
NO20050007L (no) 1-Heterosyklylalkyl-3-sulfonylazaindol eller -azaindazolderivater som 5-hydroksytryptamin-6 ligander
NO20050828L (no) lndol-3-svovelderivater
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20044763L (no) 1-(aminoalkyl)-3-sulfonylazaindoler som 5-hydroksytryptamin-6 ligander
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
NO20045589L (no) Nye forbindelser
NO20055977L (no) Nye benzimidazolderivater
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application